2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-183692
    FXR agonist 18 3061938-00-6 98%
    FXR agonist 18 is an orally active FXR agonist, with an EC50 of 10 nM against human FXR and an EC50 of 1360 nM against human TGR5. FXR agonist 18 inhibits inflammatory responses by reducing nitrite production, downregulating the expression of pro-inflammatory genes (Tnf, Adgre1, Cyp8b1, upregulating the expression of FXR, Hmox1, Nqo1, Nrf2, and enhancing antioxidant responses. FXR agonist 18 ameliorates liver fibrosis in mice, exhibits protective effects in mice with cholestatic liver injury, and shows anti-MASH efficacy. FXR agonist 18 can be used in studies of metabolic dysfunction-associated steatohepatitis.
    FXR agonist 18
  • HY-183694
    GLP-1 receptor agonist 22 3124217-40-6 98%
    GLP-1 receptor agonist 22 is an orally active GLP-1 receptor agonist. GLP-1 receptor agonist 22 promotes the accumulation of cAMP. GLP-1 receptor agonist 22 reduces blood glucose levels and inhibits feeding behavior in human glucagon-like peptide-1 receptor knock-in mice. GLP-1 receptor agonist 22 can be used in the research of type 2 diabetes and obesity.
    GLP-1 receptor agonist 22
  • HY-183701
    CD73/NTPDase1-IN-1 98%
    CD73/NTPDase1-IN-1 is a dual NTPDase1 and CD73 inhibitor, with IC50 values of 2.20 μM and 1.70 μM against human targets, respectively. CD73/NTPDase1-IN-1 can be used in the research of diseases such as inflammation, immunity and tumors.
    CD73/NTPDase1-IN-1
  • HY-183724
    MS8572 3060517-63-4
    MS8572 is a selective OTUB1 covalent ligand. MS8572 covalently modifies the noncatalytic cysteine 23 residue of OTUB1 and does not inhibit OTUB1 deubiquitinase activity. MS8572 can be used for development of deubiquitinase-targeting chimeras for targeted protein stabilization.
    MS8572
  • HY-183725
    MS5128 3060520-82-0
    MS5128 is an OTUB1-based deubiquitinase-targeting chimera (DUBTAC) targeting CFTR. MS5128 recruits OTUB1 to CFTR to induce deubiquitination and stabilization of CFTR. MS5128 can be used for the research of cystic fibrosis. (Blue: CFTR Ligand (HY-183724); Pink: OTUB1 Ligand (HY-13262); Black: Linker)
    MS5128
  • HY-183760
    AChE/BChE-IN-37
    AChE/BChE-IN-37 is a blood-brain barrier-permeable AChE/BChE inhibitor, with an IC50 of 73.65 μM against electric eel-derived AChE and an IC50 of 82.93 μM against horse-derived BChE. AChE/BChE-IN-37 exhibits chelating activity towards Cu2+, Ca2+, Mg2+, Fe2+ and Zn2+. AChE/BChE-IN-37 interacts with HSP90AA1 and GSK-3β. AChE/BChE-IN-37 inhibits the self-induced aggregation of Aβ1-42. AChE/BChE-IN-37 suppresses LPS-induced NO production in cells. AChE/BChE-IN-37 can be used in research related to Alzheimer's disease and inflammatory diseases.
    AChE/BChE-IN-37
  • HY-183763
    RORγt inverse agonist 37
    RORγt inverse agonist 37 is an orally active RORγt inverse agonist with an IC50 of 10.8 nM against human targets. RORγt inverse agonist 37 destabilizes helix 12 of RORγt in the agonist-bound conformation, thereby inhibiting transcriptional activity. RORγt inverse agonist 37 inhibits the secretion of IL-17 in cells and in LPS-induced systemic inflammation mouse models. RORγt inverse agonist 37 improves disease-related symptoms in mouse models of psoriasiform dermatitis. RORγt inverse agonist 37 can be used in research related to psoriasiform dermatitis and systemic inflammation.
    RORγt inverse agonist 37
  • HY-183764
    COX-2/5-LOX-IN-8
    COX-2/5-LOX-IN-8 is an orally active dual COX-2/5-LOX inhibitor, with an IC50 of 6.30 μM against sheep-derived COX-2 and an IC50 of 8.09 μM against 5-LOX. COX-2/5-LOX-IN-8 acts as a membrane stabilizer that stabilizes erythrocyte membranes against hypotonicity-induced hemolysis. COX-2/5-LOX-IN-8 functions as a protein stabilizer that inhibits heat-induced denaturation of bovine serum albumin. COX-2/5-LOX-IN-8 reduces paw swelling, improves hind limb weight-bearing function, decreases serum levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, CRP), and lowers serum levels of cartilage degradation biomarkers (COMP, MMP-3, CTX-II). COX-2/5-LOX-IN-8 can be used in the research of osteoarthritis.
    COX-2/5-LOX-IN-8
  • HY-183781
    RIPK1-IN-41
    RIPK1-IN-41 is an orally active RIPK1 inhibitor with an IC50 of 92 nM and a KD of 106.8 nM. RIPK1-IN-41 reduces the phosphorylation level of RIPK1, inhibits necrosome formation, blocks the activation of RIPK3 and MLKL, maintains mitochondrial and lysosomal functions, preserves cell membrane integrity, and suppresses necroptosis. RIPK1-IN-41 alleviates hypothermia and multi-organ damage in a mouse model of systemic inflammatory response syndrome induced by mTNF-α. RIPK1-IN-41 is applicable to research related to systemic inflammatory response syndrome.
    RIPK1-IN-41
  • HY-183785
    PROTAC ALK5 Degrader-1 3125240-35-6
    PROTAC ALK5 Degrader-1 is a selective ALK5 PROTAC degrader. PROTAC ALK5 Degrader-1 induces ALK5 degradation via ALK5 ATP-binding pocket engagement, CRBN recruitment, and the ubiquitin-proteasome system.PROTAC ALK5 Degrader-1 inhibits ALK5 downstream signaling. PROTAC ALK5 Degrader-1 can be used for the research of pulmonary fibrosis.
    PROTAC ALK5 Degrader-1
  • HY-183799
    GSI526 98%
    GSI526 is a IRAK4 PROTAC degrader (DC50=40.17 nM, Dmax=97%; THP-1) based on the VHL ubiquitin-proteasome system. GSI526 inhibits IRAK4-mediated NF-κB and MAPK inflammatory signaling pathways, and induces IRAK4 degradation in myeloid cells. GSI526 is applicable to inflammation-related research.
    GSI526
  • HY-183800
    JH-l-25-NH2
    JH-l-25-NH2 is an IRAK1/4 inhibitor analog derived from JH-I-25 and serves as the IRAK4-binding moiety for synthesizing VHL-recruiting and CRBN-recruiting IRAK4 PROTAC degraders.
    JH-l-25-NH2
  • HY-183809
    ZSW 3124329-46-7
    ZSW is a hexokinase 2 (HK2) inhibitor with human HK2 IC50 of 0.48 μM, human HK2 Ka of 252.00 μM, and selectivity over HK3 and GCK. ZSW binds directly to HK2, inhibits its enzymatic activity, modulates macrophage phenotypes through glycolysis inhibition, and inhibits NF-κB nuclear translocation by preventing IκBα phosphorylation and degradation. ZSW alleviates inflammatory bowel disease (IBD) and improves the intestinal inflammatory state of IBD mice. ZSW can be used for the research of inflammatory bowel disease.
    ZSW
  • HY-183839
    PROTAC STAT6 degrader-9 3077464-57-1
    PROTAC STAT6 degrader-9 is a STAT6 PROTAC degrader with a DC50 value >1 μM and a DCmax value > 0.1 μM. PROTAC STAT6 degrader-9 has the potential for application in inflammation-related diseases.
    PROTAC STAT6 degrader-9
  • HY-183847
    PROTAC STAT6 degrader-10 3077464-23-1
    PROTAC STAT6 degrader-10 is a STAT6 PROTAC degrader with a DC50 value >1 μM and a DCmax value >0.1 μM. PROTAC STAT6 degrader-10 has the potential for application in inflammation-related diseases.
    PROTAC STAT6 degrader-10
  • HY-183950
    ALK5-IN-87 2921605-02-7 98%
    ALK5-IN-87 is a potent lung-restricted ALK5 inhibitor with a pKi of 10.13. ALK5-IN-87 exerts antifibrotic activity in a mouse model of lung fibrosis. ALK5-IN-87 can be used for the research of idiopathic pulmonary fibrosis.
    ALK5-IN-87
  • HY-183952
    FPR2/ALXR agonist-1 300718-24-5
    FPR2/ALXR agonist-1 is a selective FPR2/ALXR agonist. FPR2/ALXR agonist-1 activates neutrophil superoxide production. FPR2/ALXR agonist-1 can be used for research on inflammatory diseases.
    FPR2/ALXR agonist-1
  • HY-183993
    A3AR antagonist-8 98%
    A3AR antagonist-8 is a selective A3 adenosine receptor antagonist with a Ki of 98 nM for human A3 adenosine receptor. A3AR antagonist-8 can be used for the research of glaucoma, chronic renal disease, acute renal ischemia and reperfusion injury, and cancer.
    A3AR antagonist-8
  • HY-183996
    PHD-1 ligand-1
    PHD-1 ligand-1 (Compound 1) is a PHD-1 ligand. PHD-1 ligand-1 serves as a target protein ligand for the synthesis of PHD-1 PROTAC degraders, such as SH-26 (HY-183995). PHD-1 ligand-1 is applicable to studies on ischemia/reperfusion injury.
    PHD-1 ligand-1
  • HY-184008
    FXIIa-IN-6 3107571-66-1 98%
    FXIIa-IN-6 is a potent, selective, and irreversible covalent inhibitor of Factor XIIa (FXIIa) with an IC50 of 2 nM. FXIIa-IN-6 exhibits ≥2,500-fold selectivity over related serine proteases. FXIIa-IN-6 exhibits favorable anticoagulant and anti-inflammatory activities and can be used in sepsis research.
    FXIIa-IN-6
Cat. No. Product Name / Synonyms Application Reactivity